Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version).
10.3779/j.issn.1009-3419.2020.02.01
- Author:
Caicun ZHOU
1
;
Jie WANG
2
;
Hong BU
3
;
Baocheng WANG
4
;
Baohui HAN
5
;
You LU
3
;
Zhehai WANG
6
;
Bo ZHU
7
;
Ziping WANG
8
;
Qibin SONG
9
;
Shengxiang REN
1
;
Dongmei LIN
8
;
Yayi HE
1
;
Xiaohua HU
10
;
Hongyun ZHAO
11
;
Shukui QIN
12
Author Information
1. Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
2. Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
3. West China Hospital, Sichuan University, Chengdu 610041, China.
4. NO. 960 Hospital of PLA, Jinan 250031, China.
5. Shanghai Chest Hospital, Shanghai 200030, China.
6. Shandong Caner Hospital and Institute, Jinan 250117, China.
7. Chongqing Daping Hospital, Chongqing 400042, China.
8. Beijing Cancer Hospital, Beijing 100142, China.
9. Renmin Hospital of Wuhan University, Wuhan 430060, China.
10. The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
11. Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
12. Qinhuai Medical Area, Eastern Theater General Hospital of PLA China, Nanjing 210002, China.
- Publication Type:Journal Article
- Keywords:
Cancer immunotherapy;
Immune checkpoint inhibitor;
Lung neoplasms;
PD-1/PD-L1
- From:
Chinese Journal of Lung Cancer
2020;23(2):65-76
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Improving outcomes and obtaining long-term survival are the most urgent needs of patients with advanced NSCLC. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs), especially targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), have made a breakthrough in the treatment of NSCLC, beneficial to patients' survival and changed the treatment pattern for NSCLC. It shows more and more important role in the treatment of NSCLC. Led by NSCLC expert committee of Chinese society of clinical oncology (CSCO), relevant experts in this field were organized. On the basis of referring to domestic and foreign literature, systematically evaluating the results of Chinese and foreign clinical trials, and combining the experiences of the experts, the experts group reached an agreement to develop this consensus. It will guide domestic counterparts for better application of ICIs to treat NSCLC.
